1

Natera

#906

Rank

$21.37B

Marketcap

US United States

Country

Natera
Leadership team

Dr. Matthew Rabinowitz Ph.D. (Co-Founder & Exec. Chairman)

Mr. Steven Leonard Chapman (CEO, Pres & Director)

Mr. Michael B. Brophy M.B.A. (Chief Financial Officer)

Products/ Services
Biotechnology, Genetics, Health Diagnostics, Medical
Number of Employees
1,000 - 20,000
Headquarters
San Carlos, California, United States
Established
2004
Company Registration
SEC CIK number: 0001604821
Revenue
500M - 1B
Traded as
NTRA
Social Media
Overview
Location
Summary
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
History

Natera was founded by Matthew Rabinowitz and Jonathan Sheena in 2004. Natera launched its first product, the Spectrum preimplantation genetic test, in 2009.

In 2010, the company introduced the Anora miscarriage test. Natera's advanced carrier screening test, Horizon, launched in 2012. The following year, 2013, Natera launched the Panorama non-invasive prenatal test .

In July 2015, Natera conducted an initial public offering of common stock at a price of $18.00 per share. The shares trade on the Nasdaq Global Select Market under the symbol "NTRA."In 2017, Natera launched the Vistara single-gene NIPT. That same year, Natera introduced the Signatera molecular residual disease test for research use only. The Signatera CLIA test was introduced for clinical use in 2019.

In 2018 Natera paid a $11 million fine to the department over allegations of improper billing and sales of Panorama to federal Healthcare services between the years of 2013 to 2016.Natera launched the Prospera dd-cfDNA transplant assessment test in 2019, and the Renasight kidney gene panel and the Empower hereditary cancer test in 2020.

As of May 2021, Natera has performed over 3 million cell-free DNA tests. Natera's technology has also been written about in over 100 peer-reviewed journals and publications, including Nature, Science Magazine, and the Journal of Clinical Oncology.

Mission
The mission of the company is to change the management of disease worldwide with a focus on reproductive health, cancer, and organ transplantation.
Vision
To become the world’s leading provider of innovative genetic testing, providing access to the most advanced and accurate health care services.
Key Team

Mr. Robert A. Schueren (Chief Operating Officer)

Mr. Daniel Rabinowitz L.L.M., LL.M. (Sec. & Chief Legal Officer)

Mr. Rishi Kacker (Chief Technology Officer)

Mr. Eric A. Evans (Chief Scientific Officer)

Mr. Jonathan Sheena M.Eng. (Co-Founder & Director)

Ms. Olesya A. Anisimova CPA (Chief Accounting Officer)

Mr. Phil Grinnell (VP of Sales)

Recognition and Awards
Natera has received numerous awards for its contribution to the field of genetic testing and diagnosis including the Red Herring Global Top 100 Award, the Fast Company Magazine Innovation By Design Award, and the Frost & Sullivan Incubation Award.
References
Natera
Leadership team

Dr. Matthew Rabinowitz Ph.D. (Co-Founder & Exec. Chairman)

Mr. Steven Leonard Chapman (CEO, Pres & Director)

Mr. Michael B. Brophy M.B.A. (Chief Financial Officer)

Products/ Services
Biotechnology, Genetics, Health Diagnostics, Medical
Number of Employees
1,000 - 20,000
Headquarters
San Carlos, California, United States
Established
2004
Company Registration
SEC CIK number: 0001604821
Revenue
500M - 1B
Traded as
NTRA
Social Media